Editorial Commentary: Different Strains of Bacillus Calmette-GuCrossed D sign©rin Vaccine Have Very Different Effects on Tuberculosis and on Unrelated Infections

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 960-962

  Shann, Frank ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bacillus Calmette Gu rin; BCG vaccine; heterologous immunity; immunization

Indexed keywords

BCG VACCINE;

BCG VACCINATION; COHORT ANALYSIS; GENOTYPE; GUINEA-BISSAU; HEALTH CARE PERSONNEL; HISTONE METHYLATION; HUMAN; INNATE IMMUNITY; LABORATORY TEST; MORTALITY; NEWBORN MORTALITY; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL; REVACCINATION; RURAL AREA; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; CHEMICALLY INDUCED; CICATRIX; COMMUNICABLE DISEASE; FEMALE; HOSPITALIZATION; IMMUNOLOGY; MALE; PATHOLOGY;

BCG VACCINE; CICATRIX; COMMUNICABLE DISEASES; FEMALE; HOSPITALIZATION; HUMANS; MALE;

EID: 84940662103     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ454     Document Type: Note

References (25)

1. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of costeffectiveness. Lancet 2006; 367:1173-80.
2. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348:17-24.
3. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-45.
4. Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol 2014; 15:895-9.
5. Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birthweight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245-52.
6. Biering-Sorensen S, Aaby P, Napirna B, et al. Small randomized trial among low-birthweight children of Bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 2012; 31:306-8.
7. Roth AE, Benn CS, Ravn H, et al. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ 2010; 340:c671.
8. de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis 2015; 60:1611-9.
9. Anderson EJ, Webb EL, Mawa PA, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012; 30:2083-9.
10. Garly M-L, Martins CL, Balé C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 2003; 21:2782-90.
11. Roth A, Sodemann M, Jensen H, et al. Tuberculin reaction, BCG scar, and lower female mortality. Epidemiol Camb Mass 2006; 17:562-8.
12. Roth A, Gustafson P, Nhaga A, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005; 34:540-7.
13. Sartono E, Lisse IM, Terveer EM, et al. Oral polio vaccine influences the immune response to BCG vaccination. A natural experiment. PLoS One 2010; 5:e10328.
14. Shann F. BCG vaccination in developing countries. BMJ 2010; 340:720-1.
15. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008; 32:821-41.
16. Kagina BMN, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073-9.
17. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012; 109:17537-42.
18. Jensen KJ, Larsen N, Biering-Sørensen S, et al. Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis 2015; 211:956-67.
19. Comstock GW. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine. Clin Infect Dis 2000; 30(suppl 3):S250-3.
20. Favorov M, Ali M, Tursunbayeva A, et al. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan. PLoS One 2012; 7: e32567.
21. UNICEF. Supply Division. BCG vaccine: current supply & demand outlook [Internet]. 2014. Available at: www.unicef.org/supply/files/BCG-Supply-Status-December-2014. pdf. Accessed 26 May 2015.
22. Zhang W, Zhang Y, Zheng H, et al. Genome sequencing and analysis of BCG vaccine strains. PLoS One 2013; 8:e71243.
23. Osborn TW. Changes in BCG strains. Tubercle 1983; 64:1-13.
24. Biering-Sørensen S, Jensen KJ, Aamand SH, et al. Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial. Vaccine 2015; 33:2056-65.
25. Markey K, Ho M, Rigsby P, Hockley J, Corbel M. International collaborative study to evaluate and establish WHO reference reagents for BCG vaccine of three different substrains. WHO/BS/09.2114. Geneva: WHO, 2009.